Abstract 5595: Predictive impact of sequential evaluation of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab

MLA

Atsushi Hayata, et al. “Abstract 5595: Predictive Impact of Sequential Evaluation of PD-L1-Expressing Circulating Tumor Cells in NSCLC Patients Treated with Nivolumab.” Cancer Research, vol. 78, July 2018, p. 5595. EBSCOhost, https://doi.org/10.1158/1538-7445.am2018-5595.

APA

Atsushi Hayata, Keiichiro Akamatsu, Kuninobu Kanai, Nobuyuki Yamamoto, Masanori Nakanishi, Masayuki Higuchi, Nahomi Tokudome, Yasuhiro Koh, Keita Mori, Hiroaki Akamatsu, & Hiroki Ueda. (2018). Abstract 5595: Predictive impact of sequential evaluation of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab. Cancer Research, 78, 5595. https://doi.org/10.1158/1538-7445.am2018-5595

Chicago

Atsushi Hayata, Keiichiro Akamatsu, Kuninobu Kanai, Nobuyuki Yamamoto, Masanori Nakanishi, Masayuki Higuchi, Nahomi Tokudome, et al. 2018. “Abstract 5595: Predictive Impact of Sequential Evaluation of PD-L1-Expressing Circulating Tumor Cells in NSCLC Patients Treated with Nivolumab.” Cancer Research 78 (July): 5595. doi:10.1158/1538-7445.am2018-5595.